![Erik Emerson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Erik Emerson
Directeur Général chez
GLUCOTRACK, INC.
Fortune : 863 711 $ au 30/06/2026
Profil
Erik Emerson was the founder of Symplmed Pharmaceuticals LLC, founded in 2013, serving as President & Chief Executive Officer from 2013 to 2018.
Current jobs include Chief Executive Officer & Director at GlucoTrack, Inc. starting in 2026, and Chief Executive & Director at Lokahi Therapeutics, Inc. starting in 2025.
Former jobs include Director at Adhera Therapeutics, Inc. in 2019; Marketing Director at Gilead Sciences, Inc. from 2007 to 2010; Senior Director-Commercial Development at XOMA Royalty Corp.
from 2010 to 2013; President & Director at Apimeds Pharmaceuticals US, Inc. from 2025 to 2026; Chief Commercial Officer at Mezzion Pharmaceuticals, Inc. from 2017 to 2020; and Chief Commercial Officer at Odyssey Health, Inc. from 2022 to 2023.
Education includes undergraduate studies at the University of Oregon.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
4,97 % | 15/10/2025 | 750 000 ( 4,97 % ) | 675 000 $ | 30/06/2026 |
GLUCOTRACK INC 9,45 % | 21/07/2026 | 591 570 ( 9,45 % ) | 188 711 $ | 30/06/2026 |
Postes actifs de Erik Emerson
| Sociétés | Poste | Début |
|---|---|---|
| GLUCOTRACK, INC. | Directeur Général | 14/07/2026 |
Anciens postes connus de Erik Emerson
| Sociétés | Poste | Fin |
|---|---|---|
| ODYSSEY HEALTH, INC. | Corporate Officer/Principal | 01/10/2023 |
Mezzion Pharmaceuticals, Inc.
 Mezzion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a drug manufacturing company | Corporate Officer/Principal | 01/01/2020 |
| ADHERA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 19/12/2019 |
Symplmed Pharmaceuticals LLC
 Symplmed Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Directeur Général | 01/05/2018 |
Formation de Erik Emerson
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
47
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Gilead Sciences, Inc.
 Gilead Sciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes therapeutic products and treatments for life threatening diseases | Health Technology |
XOMA Royalty Corp.
 XOMA Royalty Corp. Pharmaceuticals: MajorHealth Technology Discovers and develops antibody therapeutics | Health Technology |
GlucoTrack, Inc.
 GlucoTrack, Inc. Medical SpecialtiesHealth Technology Develops a non-invasive glucose monitoring device | Health Technology |
Odyssey Health, Inc.
 Odyssey Health, Inc. Medical SpecialtiesHealth Technology Develops heart monitoring and screening devices | Health Technology |
University of Oregon
 University of Oregon Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Adhera Therapeutics, Inc.
 Adhera Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes hypertensive drugs | Health Technology |
Symplmed Pharmaceuticals LLC
Symplmed Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Mezzion Pharmaceuticals, Inc.
Mezzion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a drug manufacturing company | Health Technology |
